ZOMETA® Helps Protect Patients With Prostate Cancer From The Threat of SREs

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumour types

About ZOMETA
Prostate Cancer
ZOMETA reduces SREs

Page

1 2

ZOMETA^® effectively helps to protect patients with prostate cancer
from the threat of SREs

Efficacy of ZOMETA^® vs placebo: median time to first SRE^2,6

ZOMETA® Increase in Survival Rate From Skeletal Fractures in Prostate Cancer Patients

ZOMETA^® significantly extended median time to first SRE by
more than 5 months vs placebo (P=.009)²
ZOMETA^® reduced the risk of SREs by 36% vs placebo (P=.002)²

ZOMETA can delay and reduce SREs in patients with prostate cancer
and bone metastases^2,6

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

ZOMETA® effectively helps to protect patients with prostate cancer from the threat of SREs

ZOMETA can delay and reduce SREs in patients with prostate cancerand bone metastases2,6

ZOMETA^® effectively helps to protect patients with prostate cancer
from the threat of SREs

ZOMETA can delay and reduce SREs in patients with prostate cancer
and bone metastases^2,6